Longitudinally extensive transverse myelitis after COVID-19 vaccination in a teenage girl


  • Arun Prasad Department of Paediatrics, All India Institute of Medical Sciences, Patna, Bihar, India https://orcid.org/0000-0002-7532-948X
  • Pradeep Kumar Department of Paediatrics, All India Institute of Medical Sciences, Patna, Bihar, India
  • Amrita Banerjee Department of Paediatrics, All India Institute of Medical Sciences, Patna, Bihar, India
  • Dipyaman Ghosh Department of Paediatrics, All India Institute of Medical Sciences, Patna, Bihar, India




Transverse myelitis, COVID-19, Vaccination, Adverse events following immunization


COVID-19 pandemic has led to the development of a variety of vaccines for protection against SARS-CoV-2 infection, with varying safety profiles and protective efficacy. As with other vaccination, vaccination against COVID-19 has also been found to be associated with various kinds of adverse events following immunization. While most adverse effects are mild, some serious side effects like transverse myelitis and acute disseminated encephalomyelitis have also been reported. However, these serious side effects have been reported in adults. To the best of our knowledge, there is no report of longitudinally extensive transverse myelitis (LETM) in the paediatric population, associated with this vaccination. We report here a case of a teenage girl, who was admitted to our hospital with the symptoms of LETM after receiving COVID-19 vaccination. Her diagnosis was based on history and, laboratory and imaging findings. She was discharged after a full recovery.


Myoung J. Two years of COVID-19 pandemic: where are we now? J Microbiol. 2022;60(3):235-7.

Tahir N, Koorapati G, Prasad S. SARS-COV-2 Vaccination-Induced Transverse Myelitis. Cureus. 2021;13(7):e16624

Khandker SS, Godman B, Jawad MI, Meghla BA, Tisha TA, Khondoker MU et al. A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines. 2021;9:1387.

"Vaccination state wise". Ministry of Health and Family Welfare. Available at: www.mohfw.gov.in. Accessed on 17 July 2022.

Guo W, Deguise J, Tian Y, Huang PC-E, Goru R, Yang Q et al. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports. Front. Pharmacol. 2022;13:870599.

Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-COV-2 vaccination: a case report and review of literature. J Neurol. 2022;269:1121-32.

Hotez Peter J, Bottazzi ME. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Ann Rev Med. 2022;73(1):55-64.

Thuluva S, Paradkar V, Gunneri SR. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase -1/2 and phase -2 trials. Lancet. 2022;1.

Maroufi SF, Behdani FN, Rezania F, Khotbehsara ST, Mirzaasgari Z. Longitudinally extensive transverse myelitis after Covid-19 vaccination: a case report and review of literature. Human Vaccines Immunotherapeutics. 2022;18(1):2040239.

Albokhari AA, Alsawas A, Adnan MH, Alasmari A Aljuhani S, Almejalli M et al. Acute inflammatory transverse myelitis post Pfizer-bioNTech-COVID-19 vaccine in a 16 year old. J Med Res Innov. 2021;5:47-50.

Gao J-J, Tseng H-P, Lin C, Shiu J-S, Lee M-H, Liu C-H. Acute transverse myelitis following COVID-19 vaccination. Vaccines. 2021;9:1008.

Vojdani A, Kharrazian D. Potential antigenic cross reactivity between SARS-COV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480.

Marino S, Taibi R, Pavone P, Marino L, Falsaperia R. Neurotropism of SARS-COV-2 and others coronavirus in children: Mechanisms and clinical manifestations. EJMO. 2021;5:91-3.

Nemoto W, Yamagata R, Nakagawasi K, Hung WY, Fujita M, Tadano T et al. Effect of spinal angiotensin-onverting enzyme 2 activation on the formalin-induced no inceptive response in mice. Eur J Pharmacol. 2020;5:172950.

Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41(3):509-18.

Rohilla R, Kakkar AK, Divyashree K, Mohindra R, Suri V. Recombinant protein subunit COVID-19 vaccine-induced Guillain-Barré Syndrome in an adolescent: A case report. Br J Clin Pharmacol. 2022;10.1111/bcp.15466.






Case Reports